{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:21:42Z","timestamp":1790846502843,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006364","name":"French National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejca.2024.114034","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T06:09:07Z","timestamp":1711087747000},"page":"114034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas"],"prefix":"10.1016","volume":"202","author":[{"given":"Alberto","family":"Picca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Touat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Belin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Gourmelon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8724-2704","authenticated-orcid":false,"given":"Vincent","family":"Harlay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0288-4607","authenticated-orcid":false,"given":"Stefania","family":"Cuzzubbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Cohen-Jonathan Moyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Bronnimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Luisa","family":"Di Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaura","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Lerond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Carpentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6564-6388","authenticated-orcid":false,"given":"Franck","family":"Bielle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Ducray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2910-4930","authenticated-orcid":false,"given":"Caroline","family":"Dehais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"noab106","key":"10.1016\/j.ejca.2024.114034_bib1","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","author":"Louis","year":"2021","journal-title":"Neuro-Oncol"},{"issue":"12 Suppl 2","key":"10.1016\/j.ejca.2024.114034_bib2","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/neuonc\/noab200","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018","volume":"23","author":"Ostrom","year":"2021","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2024.114034_bib3","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/ng.3273","article-title":"Mutational landscape and clonal architecture in grade II and III gliomas","volume":"47","author":"Suzuki","year":"2015","journal-title":"Nat Genet"},{"issue":"11","key":"10.1016\/j.ejca.2024.114034_bib4","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/S1470-2045(16)30313-8","article-title":"Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study","volume":"17","author":"Baumert","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2024.114034_bib5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1470-2045(21)00090-5","article-title":"Adjuvant and concurrent temozolomide for 1p\/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study","volume":"22","author":"Bent","year":"2021","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2024.114034_bib6","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","article-title":"Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma","volume":"374","author":"Buckner","year":"2016","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ejca.2024.114034_bib7","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1200\/JCO.21.02543","article-title":"Joint final report of EORTC 26951 and RTOG 9402: phase III trials with procarbazine, lomustine, and vincristine chemotherapy for anaplastic oligodendroglial tumors","volume":"40","author":"Lassman","year":"2022","journal-title":"JCO"},{"issue":"5","key":"10.1016\/j.ejca.2024.114034_bib8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2024.114034_bib9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2024.114034_bib10","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2001.19.9.2449","article-title":"Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy","volume":"19","author":"Chinot","year":"2001","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.114034_bib11","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/cncr.20042","article-title":"Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study","volume":"100","author":"Soffietti","year":"2004","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2024.114034_bib12","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1212\/01.WNL.0000137049.65631.DB","article-title":"Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas","volume":"63","author":"Triebels","year":"2004","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ejca.2024.114034_bib13","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/annonc\/mdg157","article-title":"Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972","volume":"14","author":"van den Bent","year":"2003","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2024.114034_bib14","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s11060-019-03194-z","article-title":"Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE\/NCCTG)","volume":"143","author":"Jaeckle","year":"2019","journal-title":"J Neurooncol"},{"issue":"5","key":"10.1016\/j.ejca.2024.114034_bib15","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s11523-020-00754-6","article-title":"Phase II trial of palbociclib in recurrent retinoblastoma-positive anaplastic oligodendroglioma: a Study from the Spanish group for research in neuro-Oncology (GEINO)","volume":"15","author":"Sep\u00falveda-S\u00e1nchez","year":"2020","journal-title":"Target Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2024.114034_bib16","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/S1470-2045(18)30362-0","article-title":"Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p\/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial","volume":"19","author":"van den Bent","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114034_bib17","first-page":"noac207","article-title":"Isocitrate dehydrogenase (IDH) mutant gliomas: a Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions","author":"Miller","year":"2022","journal-title":"Neuro-Oncol"},{"issue":"6382","key":"10.1016\/j.ejca.2024.114034_bib18","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.ejca.2024.114034_bib19","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab","volume":"5","author":"Topalian","year":"2019","journal-title":"JAMA Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2024.114034_bib20","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.2016.66.6552","article-title":"Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency","volume":"34","author":"Bouffet","year":"2016","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2024.114034_bib21","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus Nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2024.114034_bib22","first-page":"noac099","article-title":"Radiotherapy combined with Nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial","author":"Omuro","year":"2022","journal-title":"Neuro-Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2024.114034_bib23","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol"},{"issue":"6167","key":"10.1016\/j.ejca.2024.114034_bib24","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.1239947","article-title":"Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma","volume":"343","author":"Johnson","year":"2014","journal-title":"Science"},{"issue":"7804","key":"10.1016\/j.ejca.2024.114034_bib25","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41586-020-2209-9","article-title":"Mechanisms and therapeutic implications of hypermutation in gliomas","volume":"580","author":"Touat","year":"2020","journal-title":"Nature"},{"issue":"26","key":"10.1016\/j.ejca.2024.114034_bib26","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"6230","key":"10.1016\/j.ejca.2024.114034_bib27","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.ejca.2024.114034_bib28","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2024.114034_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(15)00088-1","article-title":"Immunotherapy response assessment in neuro-oncology (iRANO): a report of the RANO working group","volume":"16","author":"Okada","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2024.114034_bib30","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/sim.721","article-title":"Sample size tables for exact single-stage phase II designs","volume":"20","author":"A\u2019Hern","year":"2001","journal-title":"Stat Med"},{"issue":"6","key":"10.1016\/j.ejca.2024.114034_bib31","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"issue":"7854","key":"10.1016\/j.ejca.2024.114034_bib32","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-021-03363-z","article-title":"A vaccine targeting mutant IDH1 in newly diagnosed glioma","volume":"592","author":"Platten","year":"2021","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ejca.2024.114034_bib33","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.ejca.2024.114034_bib34","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.cell.2020.04.055","article-title":"Single-cell mapping of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes","volume":"181","author":"Friebel","year":"2020","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.ejca.2024.114034_bib35","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.cell.2020.05.007","article-title":"Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells","volume":"181","author":"Klemm","year":"2020","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.ejca.2024.114034_bib36","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/neuonc\/nox054","article-title":"Correlation of immune phenotype with IDH mutation in diffuse glioma","volume":"19","author":"Berghoff","year":"2017","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2024.114034_bib37","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1101\/gad.294991.116","article-title":"Mutant IDH1 regulates the tumor-associated immune system in gliomas","volume":"31","author":"Amankulor","year":"2017","journal-title":"Genes Dev"},{"issue":"4","key":"10.1016\/j.ejca.2024.114034_bib38","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1172\/JCI90644","article-title":"Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas","volume":"127","author":"Kohanbash","year":"2017","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.ejca.2024.114034_bib39","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/s41591-018-0095-6","article-title":"Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate","volume":"24","author":"Bunse","year":"2018","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ejca.2024.114034_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004644","article-title":"Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2\/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma","volume":"10","author":"Chuntova","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2024.114034_bib41","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41591-022-02141-2","article-title":"Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial","volume":"29","author":"Mellinghoff","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.ejca.2024.114034_bib42","doi-asserted-by":"crossref","DOI":"10.1172\/JCI139542","article-title":"Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice","volume":"131","author":"Kadiyala","year":"2021","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.ejca.2024.114034_bib43","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2159-8290.CD-21-1077","article-title":"Mutant IDH inhibits IFN\u03b3-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma","volume":"12","author":"Wu","year":"2022","journal-title":"Cancer Discov"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924006907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924006907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:10:57Z","timestamp":1727395857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924006907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":43,"alternative-id":["S0959804924006907"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114034","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114034"}}